Prizloncabtagene Autoleucel

BIOLOGICAL5 trials

Sponsors

Shanghai Tongji Hospital, Tongji University School of Medicine, Peking Union Medical College Hospital, First Affiliated Hospital of Zhejiang University, Tianjin Medical University Cancer Institute and Hospital, Shanghai AbelZeta Ltd.

Conditions

B-cell Non-Hodgkin's LymphomaNon-Hodgkin's B-cell LymphomaRelapsed/Refractory Large B-Cell Lymphoma

Phase 1

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

CompletedNCT04317885

Shanghai Tongji Hospital, Tongji University School of MedicineNon-Hodgkin's B-cell Lymphoma

Start: 2019-11-05End: 2023-12-30Updated: 2025-05-23

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

CompletedNCT04655677

Peking Union Medical College HospitalB-cell Non-Hodgkin's Lymphoma

Start: 2020-10-30End: 2024-06-30Updated: 2025-05-23

A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

First Affiliated Hospital of Zhejiang UniversityNon-Hodgkin's B-cell Lymphoma

Start: 2020-08-03End: 2024-04-30Updated: 2023-09-28

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

CompletedNCT04696432

Tianjin Medical University Cancer Institute and HospitalNon-Hodgkin's B-cell Lymphoma

Start: 2020-11-27End: 2023-12-30Updated: 2025-05-28

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

RecruitingNCT05800977

Shanghai AbelZeta Ltd.Relapsed/Refractory Large B-Cell Lymphoma

Start: 2023-02-22End: 2028-06-30Target: 112Updated: 2025-12-31

Related Papers

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Blood2025-01-1513 citations

Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).

Journal of Clinical Oncology2021-05-204 citations

Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

Blood2020-11-04